[Evaluation of the effectiveness and safety of salmeterol in children with nocturnal dyspnea].
10 children 8-16 years old (mean = 12.9) received at least 4 inhalations of short acting beta-2-mimetics and up to 100 mcg inhaled corticosteroids or/and 5 mg oral prednisone daily. Lung function test values indicated mild/severe asthma in these patients (PEFF 50-80%, FEV1 50-80%, FEV1/VC less or equal 60%). Reversibility of obstruction was at least 15% comparing to the initial values. After two weeks of this treatment resolution of dyspnoea in the night-time and significant decrease of dyspnoea in the day-time were observed. The best bronchodilatation effect was noticed in the third and fourth week of therapy. After discontinuation of Serevent significantly milder course of dyspnoea was observed.
Słomka
A
A
Centrum Pneumonologii Dzieciecej w Karpaczu.
D000280:Administration, Inhalation; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002648:Child; D004334:Drug Administration Schedule; D004417:Dyspnea / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D012129:Respiratory Function Tests; D000068299:Salmeterol Xinafoate; D012893:Sleep Wake Disorders / Q000188:drug therapy*; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D011241:Prednisone